Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Total Assets : $17.41 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Total Assets?

Panacea Life Sciences Holdings's Total Assets for the quarter that ended in Mar. 2024 was $17.41 Mil.

During the past 12 months, Panacea Life Sciences Holdings's average Total Assets Growth Rate was -1.50% per year. During the past 3 years, the average Total Assets Growth Rate was -14.30% per year.

During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average Total Assets Growth Rate was -14.30%. The lowest was -14.30%. And the median was -14.30%.

Total Assets is connected with ROA %. Panacea Life Sciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was -32.68%. Total Assets is also linked to Revenue through Asset Turnover. Panacea Life Sciences Holdings's Asset Turnover for the quarter that ended in Mar. 2024 was 0.06.

Panacea Life Sciences Holdings Total Assets Historical Data

The historical data trend for Panacea Life Sciences Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Total Assets Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Assets

31.36

23.78

19.49

17.98

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial											18.56	17.85	18.73	17.98	17.41

Panacea Life Sciences Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Panacea Life Sciences Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-8.291	+	26.275
	=	17.98

Panacea Life Sciences Holdings's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-9.623	+	27.035
	=	17.41

Panacea Life Sciences Holdings (OTCPK:PLSH) Total Assets Explanation

Total Assets is connected with ROA %.

Panacea Life Sciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-5.784	/	( (17.983	+	17.413)	/ 2 )
	=	-5.784	/	17.698
	=	-32.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Panacea Life Sciences Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	1.056	/	( (17.983	+	17.413)	/ 2 )
=	1.056	/	17.698
=	0.06

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Panacea Life Sciences Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019